DelveInsight’s, “Non-Hodgkin Lymphoma Pipeline Insight” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in the Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Non-Hodgkin Lymphoma Treatment Drugs @ Non-Hodgkin Lymphoma Pipeline Outlook
Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report
- In September 2024:- Bayer- The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.
- In September 2024:- Novartis Pharmaceuticals- This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
- August 2024:- Hoffmann-La Roche- A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma.
- August 2024:- Regeneron Pharmaceuticals- A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)
- DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working to develop 220+ pipeline therapies for Non-Hodgkin Lymphoma treatment.
- The leading Non-Hodgkin Lymphoma Companies working in the market include Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
- Promising Non-Hodgkin Lymphoma Pipeline Therapies in the various stages of development include Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.
Find out more about Non-Hodgkin Lymphoma Treatment Landscape @ Drugs for Non-Hodgkin Lymphoma Treatment
Non-Hodgkin Lymphoma Emerging Drugs Profile
- Mosunetuzumab: Hoffmann-la Roche
Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3e), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing. Mosunetuzumab is equipped with structural features that promote T-cell recruitment and retention, resulting in an antitumor effect. In preclinical models, mosunetuzumab induced T-cell proliferation and B-cell death; furthermore, efficient B-cell killing was achieved at low effector-to-target (T cell:B cell) ratios. Use of mosunetuzumab in combination with PD-L1 inhibition may address adaptive immune resistance mechanisms to enhance anticancer activity against B-cell malignancies. The drug is being evaluated in Phase III Study to evaluate the efficacy and safety of Mosunetuzumab in combination with Polatuzumab Vedotin in comparison with rituximab in combination with gemcitabine plus oxaliplatin in participants with relapsed or refractory aggressive b-cell Non-Hodgkin's Lymphoma.
- Tisagenlecleucel: Novartis
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy that involves genetically modified autologous T cells isolated from each individual patient. The reprogramming of the patient's T cells uses a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR). The CAR is comprised of a murine single-chain antibody fragment (scFv) specific for CD19, followed by a CD8 hinge and transmembrane region that is fused to the intracellular signaling domains from 4-1BB (CD137) and CD3 zeta Label. These intracellular costimulatory signaling domains increase the expansion, longer-term persistence and potency of CAR T cells: the CD3 zeta component is critical for initiating T-cell activation and antitumor activity, while 4-1BB enhances the expansion and persistence of tisagenlecleucel {FDA Label, A20379]. Upon binding to CD19-expressing cells, the CAR transmits a signal to promote T-cell expansion, activation, target cell elimination, and persistence of the tisagenlecleucel cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.
- Capivasertib: AstraZeneca
Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.
- BI-1206: BioInvent
BI-1206 is a high-affinity monoclonal antibody that selectivity binds to Fc?RIIB (CD32B), the only inhibitory member of the Fc?R family. Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma. By blocking Fc?RIIB, BI-1206 is expected to recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of these diseases. In January 2023, positive data was presented from the ongoing clinical Phase I/IIa study of BI-1206 in combination with rituximab for the treatment of non-Hodgkin’s lymphoma (NHL). Data suggest that BI-1206 restores activity of rituximab in relapsed NHL patients.
- HMPL-760: Hutchmed
HMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors.
Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment
There are approx. 200+ key Non-Hodgkin Lymphoma companies which are developing the Non-Hodgkin Lymphoma therapies. The Non-Hodgkin Lymphoma Companies which have their Non-Hodgkin Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Hoffmann-la Roche.
Learn more about the emerging Non-Hodgkin Lymphoma Pipeline Therapies @ Non-Hodgkin Lymphoma Clinical Trials Assessment
Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Dive deep into rich insights for new drugs for Non-Hodgkin Lymphoma treatment, Visit @ Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspective
Scope of the Non-Hodgkin Lymphoma Pipeline Report
- Coverage- Global
- Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Non-Hodgkin Lymphoma Companies- Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
- Non-Hodgkin Lymphoma Pipeline Therapies- Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.
For further information on the Non-Hodgkin Lymphoma pipeline therapeutics, reach out to Non-Hodgkin Lymphoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Non-Hodgkin Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Non-Hodgkin Lymphoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tisagenlecleucel: Novartis
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Capivasertib: AstraZeneca
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- BI-1206: BioInvent
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- HMPL-760: Hutchmed
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Product Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Non-Hodgkin Lymphoma Key Companies
- Non-Hodgkin Lymphoma Key Products
- Non-Hodgkin Lymphoma- Unmet Needs
- Non-Hodgkin Lymphoma- Market Drivers and Barriers
- Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
- Non-Hodgkin Lymphoma Analyst Views
- Non-Hodgkin Lymphoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
